US Gene Therapy Market - 2025-2033
US Gene Therapy Market reached US$ 2,812.92 million in 2024 and is expected to reach US$ 21,701.51 million by 2033, growing with a CAGR of 23.50% during the forecast period 2026-2033.
The US Gene Therapy Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A US Gene Therapy Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Approach
Both primary and secondary data sources have been used in the global US Gene Therapy Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
The US Gene Therapy Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A US Gene Therapy Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Approach
- In-Vivo*
- Ex vivo
- Viral Vectors*
- Adeno-Associated Virus
- Herpes Simplex Virus
- Lentivirus
- Non-Viral Vectors
- Gene Addition*
- Gene Silencing
- Gene Editing
- Rare Diseases*
- Musculoskeletal Conditions
- Blood Disorders
- Oncology
- Ophthalmology
- Others
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global US Gene Therapy Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Approach
2.4. Snippet by Vector Type
2.5. Snippet by Technique
2.6. Snippet by Application
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Growing Utilization of Advanced Delivery Vectors
3.1.1.2. Expansion of Gene Therapy Applications into the Rare Diseases
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. High Cost Associated with Gene Therapies
3.1.2.2. Safety and Long-Term Efficacy Concerns
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Personalized Cancer Gene Therapies
3.1.3.2. XX
4. IMPACT ANALYSIS
5. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
5.1. Market Leaders and Pioneers
5.1.1. Emerging Pioneers and Prominent Players
5.1.2. Established leaders with the largest-selling Brand
5.1.3. Market leaders with established Approach
5.2. CXO Perspectives
5.3. Latest Developments and Breakthroughs
5.4. Case Studies/Ongoing Research
5.5. Regulatory and Reimbursement Landscape
5.6. Porter’s Five Forces Analysis
5.7. Supply Chain Analysis
5.8. Patent Analysis
5.9. SWOT Analysis
5.10. Unmet Needs and Gaps
5.11. Recommended Strategies for Market Entry and Expansion
5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
5.13. Pricing Analysis and Price Dynamics
5.14. Key Opinion Leaders
6. US GENE THERAPY MARKET, BY APPROACH
6.1. Introduction
6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Approach
6.1.2. Market Attractiveness Index, By Approach
6.2. In-Vivo*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Ex vivo
7. US GENE THERAPY MARKET, BY VECTOR TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vector Type
7.1.2. Market Attractiveness Index, By Vector Type
7.2. Viral Vectors*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Adeno-Associated Virus
7.2.4. Herpes Simplex Virus
7.2.5. Lentivirus
7.3. Non-Viral Vectors
8. US GENE THERAPY MARKET, BY TECHNIQUE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
8.1.2. Market Attractiveness Index, By Technique
8.2. Gene Addition*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Gene Silencing
8.4. Gene Editing
9. US GENE THERAPY MARKET, BY APPLICATION
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.1.2. Market Attractiveness Index, By Application
9.2. Rare Diseases*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Musculoskeletal Conditions
9.4. Blood Disorders
9.5. Oncology
9.6. Ophthalmology
9.7. Others
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Approach Portfolios and Innovations
10.5. Company Benchmarking
11. COMPANY PROFILES
11.1. Alnylam Pharmaceuticals, Inc.
11.1.1. Company Overview
11.1.2. Approach Portfolio
11.1.2.1. Approach Description
11.1.2.2. Approach Key Performance Indicators (KPIs)
11.1.2.3. Historic and Forecasted Approach Sales
11.1.2.4. Approach Sales Volume
11.1.3. Financial Overview
11.1.3.1. Company Revenue
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Approach Development Activities
11.1.4.3. Regulatory Approvals, etc.
11.1.5. SWOT Analysis
11.2. NOVARTIS AG
11.3. Sarepta Therapeutics, Inc.
11.4. Krystal Biotech, Inc.
11.5. CSL
11.6. Bluebird Bio, Inc.
11.7. SPARK THERAPEUTICS, INC.
11.8. Ferring
11.9. Vertex Pharmaceuticals Incorporated
11.10. Amgen, Inc
11.11. Orchard Therapeutics Plc (*LIST NOT EXHAUSTIVE)
12. ASSUMPTIONS AND RESEARCH METHODOLOGY
12.1. Data Collection Methods
12.2. Data Triangulation
12.3. Forecasting Techniques
12.4. Data Verification and Validation
13. APPENDIX
13.1. About Us and Services
13.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Approach
2.4. Snippet by Vector Type
2.5. Snippet by Technique
2.6. Snippet by Application
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Growing Utilization of Advanced Delivery Vectors
3.1.1.2. Expansion of Gene Therapy Applications into the Rare Diseases
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. High Cost Associated with Gene Therapies
3.1.2.2. Safety and Long-Term Efficacy Concerns
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Personalized Cancer Gene Therapies
3.1.3.2. XX
4. IMPACT ANALYSIS
5. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
5.1. Market Leaders and Pioneers
5.1.1. Emerging Pioneers and Prominent Players
5.1.2. Established leaders with the largest-selling Brand
5.1.3. Market leaders with established Approach
5.2. CXO Perspectives
5.3. Latest Developments and Breakthroughs
5.4. Case Studies/Ongoing Research
5.5. Regulatory and Reimbursement Landscape
5.6. Porter’s Five Forces Analysis
5.7. Supply Chain Analysis
5.8. Patent Analysis
5.9. SWOT Analysis
5.10. Unmet Needs and Gaps
5.11. Recommended Strategies for Market Entry and Expansion
5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
5.13. Pricing Analysis and Price Dynamics
5.14. Key Opinion Leaders
6. US GENE THERAPY MARKET, BY APPROACH
6.1. Introduction
6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Approach
6.1.2. Market Attractiveness Index, By Approach
6.2. In-Vivo*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Ex vivo
7. US GENE THERAPY MARKET, BY VECTOR TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vector Type
7.1.2. Market Attractiveness Index, By Vector Type
7.2. Viral Vectors*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Adeno-Associated Virus
7.2.4. Herpes Simplex Virus
7.2.5. Lentivirus
7.3. Non-Viral Vectors
8. US GENE THERAPY MARKET, BY TECHNIQUE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
8.1.2. Market Attractiveness Index, By Technique
8.2. Gene Addition*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Gene Silencing
8.4. Gene Editing
9. US GENE THERAPY MARKET, BY APPLICATION
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.1.2. Market Attractiveness Index, By Application
9.2. Rare Diseases*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Musculoskeletal Conditions
9.4. Blood Disorders
9.5. Oncology
9.6. Ophthalmology
9.7. Others
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Approach Portfolios and Innovations
10.5. Company Benchmarking
11. COMPANY PROFILES
11.1. Alnylam Pharmaceuticals, Inc.
11.1.1. Company Overview
11.1.2. Approach Portfolio
11.1.2.1. Approach Description
11.1.2.2. Approach Key Performance Indicators (KPIs)
11.1.2.3. Historic and Forecasted Approach Sales
11.1.2.4. Approach Sales Volume
11.1.3. Financial Overview
11.1.3.1. Company Revenue
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Approach Development Activities
11.1.4.3. Regulatory Approvals, etc.
11.1.5. SWOT Analysis
11.2. NOVARTIS AG
11.3. Sarepta Therapeutics, Inc.
11.4. Krystal Biotech, Inc.
11.5. CSL
11.6. Bluebird Bio, Inc.
11.7. SPARK THERAPEUTICS, INC.
11.8. Ferring
11.9. Vertex Pharmaceuticals Incorporated
11.10. Amgen, Inc
11.11. Orchard Therapeutics Plc (*LIST NOT EXHAUSTIVE)
12. ASSUMPTIONS AND RESEARCH METHODOLOGY
12.1. Data Collection Methods
12.2. Data Triangulation
12.3. Forecasting Techniques
12.4. Data Verification and Validation
13. APPENDIX
13.1. About Us and Services
13.2. Contact Us
